The estimated Net Worth of Julie Clark is at least $1.17 Milion dollars as of 30 September 2021. Julie Clark owns over 4,766 units of Adverum Biotechnologies Inc stock worth over $1,158,003 and over the last 3 years Julie sold ADVM stock worth over $10,342.
Julie has made over 1 trades of the Adverum Biotechnologies Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Julie sold 4,766 units of ADVM stock worth $10,342 on 30 September 2021.
The largest trade Julie's ever made was selling 4,766 units of Adverum Biotechnologies Inc stock on 30 September 2021 worth over $10,342. On average, Julie trades about 1,589 units every 0 days since 2021. As of 30 September 2021 Julie still owns at least 164,723 units of Adverum Biotechnologies Inc stock.
You can see the complete history of Julie Clark stock trades at the bottom of the page.
Julie's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY, CA, 94063.
Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard oraz Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include: